Michael Deel

Overview:

Dr. Deel is a clinician scientist in Pediatric Hematology/Oncology. In addition to caring for pediatric patients with hematologic disorders or malignancy, his research focuses on finding novel ways to target fusion-positive pediatric sarcomas. His current work focuses on understanding the gene regulation and molecular pathways responsible for alveolar rhabdomyosarcoma, which is among the most difficult to cure pediatric cancers. Alveolar rhabdomyosarcoma is driven by chromosomal translocations t(2;13) or t(1;13) that result in oncogenic transcription factors encoding for PAX3/7-FOXO1 fusion proteins. The PAX3/7-FOXO1 oncogenes are currently not viable therapeutic targets. Using a variety of cell culture and murine models, Dr. Deel is investigating genes and pathways that regulate or coordinate PAX3/7-FOXO1-mediated tumorigenesis.

Positions:

Assistant Professor of Pediatrics

Pediatrics, Hematology-Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2010

Marshall University, Joan C. Edwards School of Medicine

Internshipand Residency, Pediatrics/University Of Louisville

University of Louisville

Pediatric Hematology/Oncology Fellowship, Pediatrics/Duke University School Of Medicine

Duke University School of Medicine

Advanced Pediatric/Oncology Research Training, Pediatrics/Duke University School Of Medicine

Duke University School of Medicine

Grants:

Preclinical studies of NUAK kinase inhibitors in fusion-positive rhabdomyosarcoma

Administered By
Pediatrics, Hematology-Oncology
Awarded By
National Pediatric Cancer Foundation, Inc.
Role
Principal Investigator
Start Date
End Date

Publications:

YAP1 IS A KEY REGULATOR OF G2/M TRANSIT IN FUSION-POSITIVE RHABDOMYOSARCOMA

Authors
Keskinyan, V; Rashid, T; Pecoraro, A; Burgess, B; Linardic, C; Deel, M
URI
https://scholars.duke.edu/individual/pub1483772
Source
manual

Hematology of Childhood and Adolescence

Authors
Bellantoni, AJ; Mangoli, A; Deel, MD
MLA Citation
Bellantoni, Andrew J., et al. “Hematology of Childhood and Adolescence.” Reference Module in Biomedical Sciences, Elsevier, 2021. Crossref, doi:10.1016/b978-0-12-818872-9.00038-8.
URI
https://scholars.duke.edu/individual/pub1496143
Source
crossref
Published Date
DOI
10.1016/b978-0-12-818872-9.00038-8

Oncology of Childhood and Adolescence

Authors
Mangoli, A; Bellantoni, AJ; Deel, MD
MLA Citation
Mangoli, Avani, et al. “Oncology of Childhood and Adolescence.” Reference Module in Biomedical Sciences, Elsevier, 2021. Crossref, doi:10.1016/b978-0-12-818872-9.00039-x.
URI
https://scholars.duke.edu/individual/pub1496144
Source
crossref
Published Date
DOI
10.1016/b978-0-12-818872-9.00039-x

More Than Meets the Eye? A Cautionary Tale of Malignant Ectomesenchymoma Treated as Low-risk Orbital Rhabdomyosarcoma.

Malignant ectomesenchymoma (MEM) is a rare multiphenotypic tumor comprised of mesenchymal and neuroectodermal components. MEM is typically diagnosed in infants and younger children and outcomes are variable. The current approach for treating MEM includes targeting the more aggressive mesenchymal component of the tumor, which is often rhabdomyosarcoma. Here, we describe a case of an orbital tumor initially diagnosed and treated as low-risk rhabdomyosarcoma. Local failure prompting a second biopsy revealed neuronal differentiation consistent with a diagnosis of MEM. Intensifying therapy and local radiotherapy led to a long-term cure. This case offers a cautionary tale that while outcomes for MEM were similar to matched rhabdomyosarcoma cohorts when treated on conventional Intergroup Rhabdomyosarcoma Study Group (IRSG) III/IV protocols, treating MEM using a decreased intensity low-risk rhabdomyosarcoma regimen may not be sufficient.
Authors
Rashid, T; Bagatell, R; Pawel, B; Bentley, RC; Kreissman, SG; Deel, MD
MLA Citation
Rashid, Tooba, et al. “More Than Meets the Eye? A Cautionary Tale of Malignant Ectomesenchymoma Treated as Low-risk Orbital Rhabdomyosarcoma.J Pediatr Hematol Oncol, vol. 43, no. 6, Aug. 2021, pp. e854–58. Pubmed, doi:10.1097/MPH.0000000000001901.
URI
https://scholars.duke.edu/individual/pub1454086
PMID
32769567
Source
pubmed
Published In
Journal of Pediatric Hematology/Oncology
Volume
43
Published Date
Start Page
e854
End Page
e858
DOI
10.1097/MPH.0000000000001901

Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force.

Rhabdomyosarcoma is the most common soft tissue sarcoma diagnosed in children and adolescents. Patients that are diagnosed with advanced or relapsed disease have exceptionally poor outcomes. The Children's Oncology Group (COG) convened a rhabdomyosarcoma new agent task force in 2020 to systematically evaluate novel agents for inclusion in phase 2 or phase 3 clinical trials for patients diagnosed with rhabdomyosarcoma, following a similar effort for Ewing sarcoma. The task force was comprised of clinicians and basic scientists who collectively identified new agents for evaluation and prioritization in clinical trial testing. Here, we report the work of the task force including the framework upon which the decisions were rendered and review the top classes of agents that were discussed. Representative agents include poly-ADP-ribose polymerase (PARP) inhibitors in combination with cytotoxic agents, mitogen-activated protein kinase (MEK) inhibitors in combination with type 1 insulin-like growth factor receptor (IGFR1) inhibitors, histone deacetylase (HDAC) inhibitors, and novel cytotoxic agents.
Authors
Pacenta, HL; Allen-Rhoades, W; Langenau, D; Houghton, PJ; Keller, C; Heske, CM; Deel, MD; Linardic, CM; Shern, JF; Stewart, E; Turpin, B; Harrison, DJ; Khan, J; Mascarenhas, L; Skapek, SX; Meyer, WH; Hawkins, DS; Chen, EY; Amatruda, JF; Hingorani, P; Laetsch, TW
MLA Citation
URI
https://scholars.duke.edu/individual/pub1477885
PMID
33915882
Source
pubmed
Published In
Journal of Clinical Medicine
Volume
10
Published Date
DOI
10.3390/jcm10071416

Research Areas:

Biomedical Engineering
Cancer
Cancer in children
Cancer--Animal models
Cancer--Treatment
Molecular Biology
Muser Mentor
Oncologists
Oncology
Pediatric hematology
Pediatricians
Rhabdomyosarcoma
Rhabdomyosarcoma, Alveolar
Rhabdomyosarcoma, Embryonal
Sarcoma
Sarcoma 180
Tumors in children